Delivery Order SPE2DB20D1100-SPE2DB25FD8A0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,824.78 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5mL) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,097.53 delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5mL) under a firm fixed price contract type. The award, issued on August 5, 2025, with completion targeted for August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical supply delivery. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $1,625.90 delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML, with an ultimate completion date of July 30, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,307.60 to AmerisourceBergen Drug Corp for the supply of Ciprofloxacin-Dexamethasone otic suspension in 7.5ml units. The contract was awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed in Conshohocken, Pennsylvania. This award represents a firm fixed-price, non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,574.71 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5ML) on August 7, 2025, with an ultimate completion date of August 8, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,451.13 for Ciprofloxacin-Dexamethasone otic suspension (7.5mL) on July 23, 2025, with completion scheduled for July 24, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension (7.5ML) with a ceiling value of $1,190.89. This competitively awarded, firm fixed-price delivery order was executed on August 1, 2025, with an ultimate completion date of August 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a $1,670.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ciprofloxacin-Dexamethasone Otic Suspension in 7.5 mL quantities. This is an unset-aside, competitively awarded contract with an ultimate completion date of July 22, 2025. The delivery order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $1,828.10 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ciprofloxacin-Dexamethasone Otic Suspension 7.5mL. This is a firm fixed-price, non-set-aside contract with performance completion scheduled for August 12, 2025, and fulfillment at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,036.52 to AmerisourceBergen Drug Corp for ciprofloxacin-dexamethasone otic suspension (7.5mL) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order for pharmaceutical products...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD8A0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,408.72 to AmerisourceBergen Drug Corp for Ciprofloxacin-Dexamethasone Otic Suspension 7.5ML, with an ultimate completion date of August 4, 2025. This non-set-aside, firm fixed-price contract was awarded on August 1, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities. The contract demonstrates the company's capability to fulfill federal medical supply requirements through competitive procurement processes and reflects DLA's strategic approach to pharmaceutical prime vendor operations supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 8/1/25 |